A 2.2-fold relative elevation of NT-proBNP from baseline successfully identified a relative reduction of LV-GLS >15% with 100% sensitivity and 81.8% specificity.
Cohort (n=74)
No
Does the combination of NT-proBNP and LV-GLS detect early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients?
The relative reduction of LV-GLS and relative elevation of NT-proBNP successfully define subclinical chemotherapy-induced cardiotoxicity 6 weeks after the first dose.
Effect estimate: AUC 0.929
p-value: p=<0.001
BACKGROUND: Chemotherapeutic agents have many side effects; among them is cardiotoxicity. Ejection fraction fails to detect the subtle alterations of left ventricular (LV) function; that is why there is a need for a more sensitive tool. The aim is to detect subclinical LV systolic dysfunction after chemotherapeutic treatment, using NT-BNP plasma level as well as speckle tracking echo-global longitudinal strain (STE-GLS). Seventy-four asymptomatic, non-metastasizing breast cancer female patients without risk factors were included. They were assessed before and 6 weeks after taking their first chemotherapeutic session. Assessment included clinical characteristics, conventional two-dimensional (2D) and three-dimensional (3D) echocardiography, and 2D STE-GLS. Blood samples for NT-BNP plasma level were collected on both visits and were later analyzed using a Sandwich ELISA technique. RESULTS: The median NT-proBNP almost doubled after 6 weeks of chemotherapy (73.50 vs 34.4 pg/L, p value 10% to less 15%) and all of them had a relatively higher NT-proBNP. A 2.2 relative elevation of the NT-proBNP was able to define a relative reduction of LV-GLS >15% by a 100% sensitivity and 81.8% specificity. CONCLUSION: The relative reduction of LV-GLS and the relative elevation of NT-proBNP were successful in defining subclinical, subtle chemotherapy-induced cardiotoxicity after 6 weeks of the first chemotherapeutic agent administration.
Sulaiman et al. (Mon,) conducted a cohort in Breast cancer (n=74). Chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Early detection of left ventricular systolic dysfunction (relative reduction of LV-GLS >15%) using relative elevation of NT-proBNP (AUC 0.929, p=<0.001). A 2.2-fold relative elevation of NT-proBNP from baseline successfully identified a relative reduction of LV-GLS >15% with 100% sensitivity and 81.8% specificity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: